{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:00:57Z","timestamp":1793926857130,"version":"4.8.0"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participants who received the 3HP regimen were recruited and examined for genotyping of CYP5A6, CYP2B6, CYP2C19, CYP2E1, and NAT2 SNPs. In our study, 184 participants (48.4%) developed ADRs. Moreover, CYP2C19 rs4986893 (TT vs. CC+CT, odds ratio [OR] [95% CI]: 2.231 [1.015\u20134.906]), CYP2E1 rs2070676 (CC vs. CG+GG, OR [95% CI]: 1.563 [1.022\u20132.389]), and CYP2E1 rs2515641 (CC vs. CT+TT, OR [95% CI]: 1.903 [1.250\u20132.898]) were associated with ADR development. In conclusion, CYP2C19 and CYP2E1 SNPs may provide useful information regarding ADRs in LTBI patients receiving the 3HP regimen.<\/jats:p>","DOI":"10.3390\/ijerph17010210","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T11:42:47Z","timestamp":1577446967000},"page":"210","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis"],"prefix":"10.3390","volume":"17","author":[{"given":"Ya-Yen","family":"Yu","sequence":"first","affiliation":[{"name":"Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan"},{"name":"Department of Clinical Laboratory, Changhua Hospital, Changhua 513, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ming","family":"Tsao","sequence":"additional","affiliation":[{"name":"Division of Chest, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan"},{"name":"Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung 402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ta","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung 403, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-5899","authenticated-orcid":false,"given":"Wei-Chang","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan"},{"name":"Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 356, Taiwan"},{"name":"Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan"},{"name":"Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung 407, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsiung","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Chest, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-7927","authenticated-orcid":false,"given":"Shun-Fa","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan"},{"name":"Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Chiou","sequence":"additional","affiliation":[{"name":"School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan"},{"name":"Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6097-3910","authenticated-orcid":false,"given":"Yi-Wen","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan"},{"name":"Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. Who global surveillance and monitoring project","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention (CDC) (2011). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR. Morb. Mortal. Wkly. Rep., 60, 1650\u20131653."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jac\/dky403","article-title":"Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: A decision analysis study","volume":"74","author":"Doan","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Sterling","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the prevent tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e4126","DOI":"10.1097\/MD.0000000000004126","article-title":"Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr. Med Res. Opin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","article-title":"Inhibition of cytochrome p450 (cyp450) isoforms by isoniazid: Potent inhibition of cyp2c19 and cyp3a","volume":"45","author":"Desta","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00228-001-0396-3","article-title":"Isoniazid is a mechanism-based inhibitor of cytochrome p450 1a2, 2a6, 2c19 and 3a4 isoforms in human liver microsomes","volume":"57","author":"Wen","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tung, M.C., Wen, Y.C., Wang, S.S., Lin, Y.W., Chow, J.M., Yang, S.F., and Chien, M.H. (2019). Impact of long non-coding RNA hotair genetic variants on the susceptibility and clinicopathologic characteristics of patients with urothelial cell carcinoma. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030282"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome p450 3a4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/03602532.2014.984070","article-title":"Pharmacogenetics of isoniazid-induced hepatotoxicity","volume":"47","author":"Perwitasari","year":"2015","journal-title":"Drug Metab. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.apsb.2016.07.014","article-title":"Isoniazid metabolism and hepatotoxicity","volume":"6","author":"Wang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijid.2014.04.011","article-title":"Association of the cyp2b6 gene with anti-tuberculosis drug-induced hepatotoxicity in a brazilian amazon population","volume":"33","author":"Fernandes","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1128\/AAC.43.12.2922","article-title":"High-dose isoniazid therapy for isoniazid-resistant murine mycobacterium tuberculosis infection","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"Weiner","year":"2003","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1164\/rccm.200201-047OC","article-title":"A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment","volume":"165","author":"Bock","year":"2002","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1164\/rccm.201412-2257ED","article-title":"Optimizing the dose of rifapentine to treat tuberculosis. It\u2019s elementary","volume":"191","author":"Lauzardo","year":"2015","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"Weiner","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in hiv-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciy082","article-title":"Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine","volume":"67","author":"Brooks","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200225080-00002","article-title":"Genotyping of drug targets: A method to predict adverse drug reactions?","volume":"25","author":"Guzey","year":"2002","journal-title":"Drug Saf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2174\/1568026043387791","article-title":"Genotyping as a tool to predict adverse drug reactions","volume":"4","author":"Guzey","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/ajhp\/57.9.887","article-title":"Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications","volume":"57","author":"Rioux","year":"2000","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/gm409","article-title":"Pharmacogenomics of adverse drug reactions","volume":"5","author":"Daly","year":"2013","journal-title":"Genome Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2133\/dmpk.17.357","article-title":"Genotyping of the n-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in japanese patients","volume":"17","author":"Hiratsuka","year":"2002","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_31","first-page":"803","article-title":"Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients","volume":"25","author":"Sotsuka","year":"2011","journal-title":"In Vivo (Athens, Greece)"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/1\/210\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:46:12Z","timestamp":1760190372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/1\/210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["ijerph17010210"],"URL":"https:\/\/doi.org\/10.3390\/ijerph17010210","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,27]]}}}